Immunocore Holdings plc (NASDAQ:IMCR) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Immunocore Holdings plc (NASDAQ:IMCR) have received a consensus recommendation of “Moderate Buy” from the thirteen research firms that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and eight have given a buy recommendation to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $65.64.

A number of research firms recently commented on IMCR. HC Wainwright reaffirmed a “buy” rating and issued a $100.00 target price on shares of Immunocore in a research report on Wednesday, March 12th. Morgan Stanley reiterated an “equal weight” rating and set a $35.00 target price on shares of Immunocore in a research report on Friday, March 7th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $71.00 target price on shares of Immunocore in a research report on Wednesday, March 12th.

Insiders Place Their Bets

In other Immunocore news, Director Bros. Advisors Lp Baker bought 807,338 shares of the company’s stock in a transaction on Monday, March 17th. The shares were bought at an average price of $29.72 per share, for a total transaction of $23,994,085.36. Following the transaction, the director now owns 2,144,060 shares of the company’s stock, valued at approximately $63,721,463.20. This trade represents a 60.40 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 9.10% of the stock is owned by insiders.

Institutional Trading of Immunocore

Several hedge funds have recently modified their holdings of the business. GSA Capital Partners LLP purchased a new position in Immunocore in the third quarter worth $406,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its holdings in shares of Immunocore by 7.5% in the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 427,152 shares of the company’s stock valued at $13,297,000 after purchasing an additional 29,689 shares in the last quarter. Primecap Management Co. CA lifted its stake in shares of Immunocore by 26.7% in the third quarter. Primecap Management Co. CA now owns 2,472,020 shares of the company’s stock valued at $76,954,000 after purchasing an additional 520,950 shares during the period. Massachusetts Financial Services Co. MA boosted its holdings in Immunocore by 27.6% during the third quarter. Massachusetts Financial Services Co. MA now owns 498,221 shares of the company’s stock worth $15,510,000 after buying an additional 107,656 shares in the last quarter. Finally, HealthInvest Partners AB grew its position in Immunocore by 127.4% during the third quarter. HealthInvest Partners AB now owns 54,060 shares of the company’s stock worth $1,683,000 after buying an additional 30,282 shares during the period. 84.50% of the stock is owned by institutional investors and hedge funds.

Immunocore Stock Performance

Shares of Immunocore stock opened at $30.13 on Friday. The company has a quick ratio of 3.76, a current ratio of 3.78 and a debt-to-equity ratio of 1.03. Immunocore has a 52 week low of $27.19 and a 52 week high of $66.00. The firm’s 50 day moving average is $30.02 and its two-hundred day moving average is $31.01. The firm has a market capitalization of $1.51 billion, a P/E ratio of -31.72 and a beta of 0.79.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.